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ABSTRACT
Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel in the apical surface of
epithelial cells in the airway and gastrointestinal tract, and mutation of CFTR is the underlying cause of
cystic fibrosis. However, the precise molecular details of the structure and function of CFTR in native and
disease states remains elusive and cystic fibrosis researchers are hindered by a lack of high specificity,
high affinity binding reagents for use in structural and biological studies. Here, we describe a panel of
synthetic antigen-binding fragments (Fabs) isolated from a phage-displayed library that are specific for
intracellular domains of CFTR that include the nucleotide-binding domains (NBD1 and NBD2), the R-
region, and the regulatory insertion loop of NBD1. Binding assays performed under conditions that
promote the native fold of the protein demonstrated that all Fabs recognized full-length CFTR. However,
only the NBD1-specific Fab recognized denatured CFTR by western blot, suggesting a conformational
epitope requirement for the other Fabs. Surface plasmon resonance experiments showed that the R-
region Fab binds with high affinity to both the phosphorylated and unphosphorylated R-region. In
addition, NMR analysis of bound versus unbound R-region revealed a distinct conformational effect upon
Fab binding. We further defined residues involved with antibody recognition using an overlapping
peptide array. In summary, we describe methodology complementary to previous hybridoma-based
efforts to develop antibody reagents to CFTR, and introduce a synthetic antibody panel to aid structural
and biological studies.
Abbreviations: ATP, adenosine triphosphate; BSA, bovine serum albumin; CDR, complementarity-determining
region; CFTR, cystic fibrosis conductance regulator; DTT, dithiothreitol; ELISA, enzyme-linked immunosorbant assay;
Fab, antigen-binding fragment; H3PO4, phosphoric acid; ICD, intracellular domain; MgCl2, magnesium chloride; MSD,
membrane-spanning domain; NaCl, sodium chloride; NBD, nucleotide-binding domain; NMR, nuclear magnetic res-
onance; PBS, phosphate-buffered saline; PKA, protein kinase A; R-region, regulatory region; RE, regulatory exten-
sion; RI, regulatory insertion; RNA, ribonucleic acid; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
electrophoresis; SPR, surface plasmon resonance
KEYWORDS
Cystic fibrosis conductance
regulator; membrane
protein; phage display;
protein engineering;
synthetic antibody
Introduction
The cystic fibrosis transmembrane conductance regulator (CFTR)
is a large multidomain protein belonging to the ABC transporter
superfamily, and mutation of the CFTR gene is the underlying
cause of cystic fibrosis. 1 CFTR plays an important role as an epi-
thelial anion channel, regulating the transport of chloride ions at
epithelial surfaces. The absence of functional CFTR results in dis-
ruption of ionic and water homeostasis at epithelial surfaces, inter-
fering with normal function of the lungs, pancreas, intestines and
other glandular epithelia. 2 Although high-resolution structure
determination of CFTR remains elusive, insight into channel struc-
ture and function has been derived from electronmicroscopy stud-
ies of the full-length channel protein and NMR and X-ray
crystallography studies on individual channel domains. 3-7
As with other members of the ABC transporter family,
CFTR has 2 membrane spanning domains (MSD1 and MSD2)
and 2 intracellular nucleotide-binding domains (NBD1 and
NBD2) (Fig. 1). 8 Extensions of the transmembrane helices into
the cytoplasm form intracellular domains (ICDs) containing
short coupling helices, which interact with the NBDs, and ATP
binding sites are formed at the interface of the NBD hetero-
dimer. The C-terminal end of NBD1 is also linked to MSD2
through a 200-residue region known as the regulatory (R)
region, a highly dynamic, intrinsically disordered region
containing multiple sites for phosphorylation by protein kinase
A (PKA). 9 The N-terminal 30 residues of the R-region have
been termed the regulatory extension (RE) of NBD1. An
additional PKA phosphorylation site is present in the NBD1
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regulatory insertion (RI), a 32-residue loop between the first 2 b
strands of the domain. Together, the R-region and RI form
highly dynamic phospho-regulatory elements that are hypothe-
sized to modulate NBD interactions and structure, which in
turn determine CFTR stability and regulate function. For exam-
ple, NMR data indicate that a high phosphorylation state of the
R-region promotes a reduced helical state that in turn reduces
its interaction with NBD1 7 and promotes channel opening.
The Phe508 side-chain of NBD1 is also hypothesized to affect
channel stability, and is believed to mediate critical interactions
with the cytoplasmic loops of the membrane spanning domain.
8 The importance of this residue is highlighted by its deletion
in the majority of cystic fibrosis patients, which results in a
thermodynamically unstable protein subject to removal by
quality-control mechanisms in the cell. 2,10-13 This thermal
instability remains a major barrier to progress in cystic fibrosis
research, and to the development of effective therapeutics.
Despite intense study, the mechanism of action of CFTR is still
not fully understood. 2 Although crystal structures often provide
important insights into the mechanism of action of therapeuti-
cally relevant proteins, the properties of membrane proteins such
as CFTR make structural elucidation extremely difficult. 7,14 The
binding of antibody fragments to membrane proteins can help
overcome the problems that make membrane proteins difficult to
crystallize. For example, synthetic antibody fragments have
enabled high-resolution structure determination of membrane
proteins, including the potassium channel protein KcsA, 15 and
also large functional RNAmolecules that similarly exhibit confor-
mational flexibility. 16 However, the use of crystallization chaper-
ones to facilitate structural studies of CFTR has been hampered
by a lack of suitable antibody reagents. Although monoclonal
antibodies to CFTR have been isolated, 17-19 they do not distin-
guish between mutant and native conformational states of CFTR.
Moreover, current mouse antibodies to CFTR give weak binding
signals to the channel protein in airways, where the physiological
expression levels tend to be relatively low. 20,21 Importantly, assays
to elucidate biological pathways and cellular function may also be
hindered by a lack of high affinity reagents to probe protein func-
tion and cellular localization.
A possible explanation for this low recognition by conven-
tional antibodies may be limitations of affinity or weak
cross-reactivity to fully-native epitopes, which could potentially
arise from the inability to control buffer environment during
immune antigen challenge and in vivo antibody elicitation. Gen-
eration of monoclonal antibodies through mouse hybridoma
technology is limited by the constraints of the immune system.
In contrast, synthetic antibody technologies have emerged as a
powerful method for rapid in vitro generation of high affinity
recombinant antibodies. 22 Recombinant antibodies generated
from in vitro selections against CFTR antigens using precisely
controlled buffer conditions could potentially select antibodies
with better affinities or specificity to native CFTR than has been
possible with hybridoma methods.
Here, we outline approaches to systematically isolate syn-
thetic antibodies capable of specific recognition of individual
CFTR domains, describe assays for characterization of these
antibodies, and report recombinant antibody fragments that
will aid the cystic fibrosis research community to characterize
the structure and function of CFTR.
Results
Selection of synthetic fabs binding to CFTR domains
We cycled library F, a previously described synthetic Fab-phage
library, 23 through 4 rounds of binding selections against recom-
binant proteins representing the R-region and 2 nucleotide-bind-
ing domains (NBD1 and NBD2) of CFTR. Individual phage
clones from the third and fourth selection rounds were screened
for specific binding by phage ELISA. Although enrichment for
specific binding Fab-phage to NBDs was low at 3%, which is
likely attributable to the conformational heterogeneity of the
NBDs as soluble, individual domains, specific Fabs to each
domain were identified from the selections (Fig. 2b and 2d).
Five unique Fab sequences were identified for binding to the
R-region and phosphorylated R-region antigens (Figs. 2a – 2c).
Of the selected 30 specific binding clonal phage-Fabs
sequenced, phage-Fab AB6 was observed most frequently (26/
30 sequences), and phage-Fab AG6 showed the highest inhibi-
tion of ELISA binding to phosphorylated R-region when
100 nM of competing antigen was present in solution (Fig. 2c).
Subsequent kinetic analysis by surface plasmon resonance
(SPR) showed that Fab AG6 binds tightly to R-region antigens,
with KD values of 32 nM and 8.7 nM for R-region or phosphor-
ylated R-region, respectively (Fig. 3).
To overcome the insolubility of NBD1, the regulatory
insertion within the NBD1 domain may be deleted. Alterna-
tively, compensating solubilizing mutations can be introduced
into the full-length NBD1 protein. We examined the ability of
phage-displayed Fab BB9 to bind to different NBD1 domains
containing these mutations (Fig. 2d). The greatest ELISA
binding signal was observed for full-length NBD1 containing 3
solubilizing mutations (NBD1 3sol), although binding
signal was also observed for NBD1 domains containing
Figure 1. Structural features of CFTR. The domain organization of CFTR is
illustrated as a cartoon. Membrane-spanning domains (MSD) extend to the intra-
cellular domains (ICDs), which in turn interact with nucleotide-binding domains 1
and 2 (NBD1 and NBD2). The regulatory extension (RE) of NBD1 and phospho-reg-
ulatory elements, including the regulatory insertion (RI) of NBD1 and the regula-
tory region (R-region), are also highlighted.
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deletions of the regulatory insertion, regulatory extension, and
residue F508 deletions (NBD1 del RI RE and NBD1 del RI RE
F508).
We also performed binding selections against a biotinylated
peptide corresponding to the regulatory insertion of NBD1 and
identified 3 unique clones that bound the antigen in phage
ELISAs (Fig. 2b). Two of the Fabs (E5 and G5) contained
identical complementarity-determining region (CDR) H1 and
H3 sequences and differed only in CDR H2 and L3, while the
sequence of the third Fab (A6) was unique in all 4 CDRs that
Figure 2. Fabs binding to recombinant CFTR domains. (A) Framework sequences of variable domains. VH and VL sequences are numbered according to IMGT database
(http://www.imgt.org/IMGTScientificChart/Numbering/IMGT-Kabat_part1.html). Asterisks () indicate diversified CDR regions. (B) CDR sequences of Fabs. Positions
randomized within each CDR in library F are shown at the top of each column, numbered according to IMGT standards. 37 (C) Fab-phage ELISAs for indicated Fabs binding
to the CFTR domain antigens against which they were raised in the presence of the same antigens in solution at the indicated concentrations. Fabs marked with an aster-
isk () were chosen for further evaluation. (D) Fab-phage ELISAs for Fab BB9 binding to NBD1 variant containing 3 solubilizing mutations (3sol), regulatory insertion and
regulatory element deletions (del RI RE), or these deletions and deletion of residue Phe508 (del RI RE F508), in the presence of the same antigens in solution at the
indicated concentrations. (E) ELISAs for binding of the indicated purified Fab proteins to the biotinylated NBD1 RI peptide immobilized on SAV-coated plates (closed
squares) or to SAV (open circles).
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were diversified in library F. Specificity of each of the 3 Fabs for
the antigen was confirmed by ELISA (Fig. 2e).
NMR analysis of fab AG6 binding to R-region
and phosphorylated R-region
To examine the global effect of Fab AG6 binding to the
R-region, NMR proton-nitrogen correlation (HSQC) spectra
were examined for R-region and phosphorylated R-region in the
absence or presence of Fab (Fig. 4a). The combined 1H, 13C and
15N chemical shift changes of R-region proteins in the presence
or absence of Fab AG6 (Fig. 4c and 4e) were determined, along
with the intensity ratios (Fig. 4b and 4d). Based on intensity ratios,
with a value of 1.0 representing no intensity change upon Fab
binding, the NMR data reveal that Fab AG6 binding affects both
N and C-terminal segments (residues 650–680 and 770–830) of
the R-region. The dominant chemical shift changes at the R-
region C-terminal segment suggest direct interactions with these
Figure 4. NMR analysis of Fab AG6 binding to R-region or phosphorylated R-region. (A) HSQC spectra of unphosphorylated (left) or phosphorylated (right) R-region in the
absence (black) or presence (red) of Fab AG6. The ratio of intensity changes upon Fab AG6 binding to unphosphorylated (B) and phosphorylated R-region (D), with solid
lines representing the baseline value of one, indicating no Fab binding with no change in the intensity, and error bars reflecting the propagation error from the experi-
mental data. Combined 1H,13C and 15N chemical shift changes in Hz upon Fab AG6 binding to unphosphorylated (C) or phosphorylated R-region (E), with solid lines
representing the average value and dashed lines corresponding to a value plus one standard deviation from the average. In (B-E), PKA phosphorylation sites are marked
as stars, open for the unphosphorylated and filled for the phosphorylated state.
Figure 3. Kinetic analysis of Fab AG6 binding to R-region or phosphorylated R-region. (A) SPR traces for serial dilutions of Fab AG6 binding to immobilized R-region or
phosphorylated R-region. (B) Kinetic parameters (ka and kd) and dissociation constants (KD) determined by globally fitting a reference cell-subtracted concentration series
to a 1:1 (Langmuir) binding model. See Materials and Methods for details.
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residues that lead to a stable, high-affinity complex, while other
residues in the R-region likely are affected due to transient tertiary
contacts with the R-region C-terminus or Fab and remain
dynamic. Analysis of the direction of the amide nitrogen and car-
bonyl chemical shifts at the R-region C-terminus suggests moving
from transient fractional helical conformations in the free state to
an extended conformation in the Fab-bound states (Fig. S1).
Because unphosphorylated R-region has more pronounced heli-
cal character in this segment than the phosphorylated state,7 the
chemical shift signature for this conformational change is more
robust in the unphosphorylated state.
Epitope mapping of CFTR specific fabs using overlapping
peptide arrays
We mapped the epitopes of the Fabs by assessing binding to a
series of overlapping peptides representing the linear amino
acid sequence of CFTR (Fig. 5 and Table S1). Regulatory inser-
tion specific Fabs A6, E5, and G5, selected against N-terminally
biotinylated peptide, showed only weak binding to a single
peptide within the array (Fig. 5a, residues 396–410 and
Table S1, peptide 44), suggesting a requirement for secondary
structure within the binding epitope. In agreement with the
NMR spectral changes that indicate an effect of Fab AG6 bind-
ing on C-terminal residues, we observed strong binding of Fab
AG6 to 2 peptides representing the C-terminal region of CFTR
(Fig. 5b, residues 836–855 and Table S1b, peptides 130 and
131). Anti-NBD1 Fab BB9 showed binding to peptides flanking
residues involved in the formation of the core ATP binding
region of NBD1 (Fig. 5c, residues 556–585 and Table S1c, pep-
tides 76–79). In contrast, Fab AC10 did not show strong bind-
ing signals to overlapping peptides spanning the NBD2 domain
(Fig. 5d and Table S1d).
Binding of fabs to full-length CFTR
The Fab panel was assayed for recognition of full-length CFTR
protein using an ELISA performed under detergent solubilizing
conditions that maintain the native fold of CFTR (Fig. 6a). In
addition, full-length CFTR protein was subjected to denaturing
SDS-PAGE for western blot analysis with the synthetic Fabs
and a positive control mouse anti-CFTR monoclonal antibody
Figure 5. Binding of anti-CFTR Fabs to linear peptide arrays. Fab proteins were assayed for their ability to bind to a series of overlapping peptides representing the
cytosolic sequence of CFTR. Individual peptides are represented by shaded rectangles, with black representing high binding signals and white representing low binding
signals. Precise peptide boundaries and binding signals are listed in Table S1. (A) Fab A6 (top), Fab E5 (middle), and Fab G5 (bottom) were assayed for binding to overlap-
ping peptides covering residues 396–445. (B) Fab AG6 was assayed for binding to overlapping peptides covering residues 661–947. (C) Fab BB9 was assayed for binding
to overlapping peptides covering residues 287–690. (D) Fab AC10 was assayed for binding to overlapping peptides covering residues 1181–1455.
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596 (Fig. 6b). All six of the Fabs that were tested showed bind-
ing to full-length CFTR under conditions promoting channel
folding, but only Fab BB9 showed binding by protein gel blot.
These results indicate that Fab BB9 likely recognizes a linear
epitope of NBD1 that includes residues within the peptides
exhibiting binding to Fab BB9 in the overlapping peptide array
(Fig. 5c). In contrast, Fab AC10 likely recognizes a conforma-
tional epitope, as supported by a lack of reactivity to linear pep-
tides of NBD2 (Fig. 5d). Taken together with the results of our
NMR studies (Fig. 4 and Fig. S1) and overlapping peptide
arrays (Fig. 5b), Fab AG6 likely recognizes a complex epitope
including linear regions within the R-region C-terminus
(Fig. 5b Fig. S1). Upon binding to this region, Fab AG6 may
induce a structural change affecting the N-terminal conforma-
tion of the protein as well (Fig. 4b). The regions or residues
that form the complete Fab AG6 epitope are likely brought
together within the context of the folded full-length channel
protein, enabling high affinity recognition of the R-region by
Fab AG6 (Fig. 3). Finally, although Fabs A6, E5 and G5 were
selected against a synthetic peptide, their inability to recognize
denatured CFTR in western blot analysis (Fig. 6b) and the lack
of significant binding to peptides in the overlapping peptide
array (Fig. 5a and Table S1a), suggests that a secondary
structure within the NBD1 regulatory insertion may be
required for efficient binding.
Discussion
An important advantage of in vitro phage display methods over
traditional antibody hybridoma methods is the ability to tailor
selection conditions to individual antigens. The CFTR channel
protein contains highly mobile and disordered regions, has
high dependence on a membrane environment for native struc-
ture, and has a very limited exposed external surface area.2
These factors make preserving the native structure of CFTR
during immunization very challenging and are likely central to
the inability of previously isolated anti-CFTR antibodies to rec-
ognize external, discontinuous, or conformationally sensitive
epitopes. However, in vitro approaches with controlled buffer
conditions, such as those reported here, can enable develop-
ment of antibodies capable of distinguishing conformational
epitopes. We have demonstrated the application of synthetic in
vitro phage-displayed antibody libraries to develop a panel of
human antibodies specific for individual domains of CFTR,
including NBD1, the NBD1 regulatory insertion loop, NBD2
and the R-region. We show that these Fabs can bind with high
affinity to modulate structural changes upon binding (R-region
specific Fab AG6) and to distinguish between unfolded (Fab
BB9) and folded (Fabs AC10, AG6, E5, G5, and A6) full-length
CFTR.
These antibodies are not only valuable affinity reagents that
enable protein detection, but are also potentially valuable for
structural studies of CFTR. The properties that make CFTR a
challenging protein for antibody generation also contribute to
difficulties in forming crystal contacts in high-resolution X-ray
crystallography studies. However, binding of antibody frag-
ments to both soluble and membrane protein has enabled
X-ray diffracting crystals to be obtained in many cases. 15,16
More recently, Fabs have been crucial as stabilizers and symme-
try determinants in single particle structure determination of
proteins by cryo-electron microscopy. 24,25 Successful structural
elucidation of CFTR would undoubtedly provide valuable
insight into its mechanism of action and could aid drug design
efforts. Moreover, given that CFTR is unique as an ABC trans-
porter that functions as an ion channel, structural insights
would also be intriguing from an evolutionary viewpoint.
The methods outlined here may also serve as an outline for
future work aimed at isolating additional CFTR-specific anti-
bodies that have proved elusive with hybridoma techniques,
such as antibodies capable of distinguishing between wild-type
CFTR and the DF508 mutant. Given that the majority of
patients affected by cystic fibrosis possess the DF508 CFTR
Figure 6. Fabs binding to full-length CFTR. (A) ELISAs for Fabs binding to the full-length CFTR protein under detergent conditions that maintain native folding. An
anti-Her2 Fab was used as a negative control. (B) Western blots for Fabs binding to denatured full-length CFTR. An anti-CFTR mouse monoclonal antibody (596) was used
as a positive control. See Materials and Methods for details.
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mutation, high affinity reagents able to specifically detect this
mutation could prove valuable in both research and clinical
efforts. The F508 side-chain has been hypothesized to mediate
critical interactions with the cytoplasmic loops of the mem-
brane spanning domain, 8 and studies suggest that the DF508
mutation affects the biosynthetic pathway and conformational
state of CFTR, such that the mutant protein is unable to pass
through the endoplasmic reticulum quality control and is sub-
sequently degraded. 2,10, 12 In addition, the DF508 mutant is
thermodynamically unstable, and this instability contributes to
the removal of mutant CFTR by quality control mechanisms in
the cell 11,13, 26 and is a major challenge for therapeutic develop-
ment. One method to overcome the thermal instability of
mutant CFTR proteins is to employ ligands that bind with high
affinity to unstable regions of the protein. Although small mol-
ecules are more typically screened as stabilizing agents, peptides
and proteins can also fulfill this role with antibody binding able
to stabilize mobile or disordered regions of protein antigens, 27
and antibody fragments have been used to perturb intracellular
functions. 28,29 Moreover, specific in vitro selection conditions
described in this work can be combined with engineering of
large combinatorial protein libraries 30 to advance opportuni-
ties for tailoring antibody fragments as stabilizing intrabody
agents.
Materials and methods
CFTR antigens
Human NBD1 (NBD1 del RI del RE: 387–646, D405–436, with
and without F508del, or NBD1 3sol: 389–678, F429S, F494N,
Q637R) proteins were expressed as His6-SUMO fusions at
16C in Escherichia coli BL21(DE3) Codon Plus cells grown in
LB media and were purified as previously described. 6,31 Three
different NDB1 antigens were purified that contained either
deletions of the regulatory insertion and regulatory extension
regions, or residue F508 or NBD1 containing the regulatory
insertion and regulatory extension with 3 solubilizing muta-
tions introduced.
R-region and phosphorylated R-region protein domains
were expressed and purified as previously described. 7
The NBD1 regulatory insertion peptide was synthesized
with an N-terminal biotin as the following amino acid
sequence: Biotin-FGELFEKAKQNNNNRKTSNGDDSLFFSNF
SLC-OH.
The NBD2 domain of CFTR (residues 1193–1445) contains
5 solubility mutations (Q1280E/Y1307N/H1402A/Q1411D/
L1436D) (constructed by Structural GenomiX) and was
expressed as previously described 32 with changes including the
use of Arctic Express DE3 RIL cells and buffers containing
20 mM sodium phosphate (pH 7.5), 100 mM Arg, and 2% (w/
v) glycine.
Fab-phage binding selections and screening
Binding selections were performed using Library F, 23 a single
framework human Fab library constructed similarly to previ-
ously described libraries. 33,34 Briefly, a phagemid vector was
engineered for bivalent display of a human Fab on the pIII
protein of the M13 bacteriophage. All three heavy chain CDRs
and the light chain CDR3 were mutagenized using oligonucleo-
tide-directed mutagenesis with tailored mutagenic oligonucleo-
tide mixtures. Solvent-accessible residues of CDRs H1 and H2
were restricted to tyrosine and serine residues, whereas CDRs
H3 and L3 were allowed a much more complex chemical diver-
sity of the following composition: 25% Tyr, 20% Ser, 20% Gly,
10% Ala, and 5% each of Phe, Trp, His, Pro and Val. The CDR
H3 and L3 lengths were varied between 5 to 22 or 8 to 12 resi-
dues, respectively.
Library F was cycled through 4 rounds of binding selections
according to modified protocols. 23 CFTR domains and phage
library pools that were exposed to CFTR antigens were main-
tained in the following buffer conditions: NBD domains,
50 mM NaPi pH 7.0, 150 mM NaCl, 2% glycerol, 5 mM MgCl2,
5 mM ATP, 5 mM DTT added immediately before use; R-
region, 20 mM HEPES pH 7.5, 150 mM NaCl, 4 mM benzami-
dine, 2 mM DTT added immediately before use; CFTR regula-
tory insertion peptide, phosphate-buffered saline (PBS). Prior
to resuspension of library phage for selection steps, 0.5% bovine
serum albumin (BSA) was added to each solution.
Each selection round consisted of a negative selection step
on 96-well Maxisorp immunoplate wells (Fisher Scientific)
coated with 1% BSA in the appropriate selection buffer to
remove non-specific binding Fab-phage, followed by a positive
selection step on antigen-coated ELISA wells. Antigen coating
was performed overnight at 4C, phage were incubated in anti-
gen-coated wells for 1–2 hours at 4C, and all wash steps were
performed with the appropriate selection buffer at 4C. For
peptide selections, library phage were subjected to negative
selection in streptavidin- or neutravidin-coated wells and
unbound phage were transferred to wells containing biotiny-
lated peptide captured with coated streptavidin or neutravidin.
Selection stringency was increased by increasing the number of
wash steps with each subsequent round of selection. Bound
phage were eluted from antigen-coated wells with 100 mM HCl
and neutralized with 1 M Tris pH 8.0.
Selected phage pools were amplified as previously described.
35 Briefly, E. coli XL1blue cultures were grown to an OD600 of
0.8 in 2YT media containing 10 mg/ml tetracycline and infected
with neutralized phage eluates. Cultures were incubated for
30 minutes at 37C with gentle shaking and approximately 1010
cfu of M13 K07 helper phage were added. Cultures were incu-
bated for 45 minutes at 37C with shaking at 200 rpm and were
transferred to 40 ml 2YT media supplemented with 100 mg/ml
carbenicillin and 25 mg/ml kanamycin. Cultures were grown
overnight at 37C with shaking at 200 rpm. The amplified
phage pool was harvested for subsequent selection rounds as
described. 35
Antigen-binding Fab-phage were identified by clonal phage
ELISAs. Clonal bacterial cultures harboring phagemid were
grown overnight at 37C in 96-well deep well plates with 2YT
media containing 100 mg/ml carbenicillin and 1010 cfu/ml of
M13 K07 helper phage. Phage ELISAs were performed using
antigen coating, blocking, and phage incubation conditions sim-
ilar to those used during binding selections. After washing, anti-
M13-HRP (GE Healthcare, Piscataway, NJ) was diluted in
appropriate buffer (DTT was omitted during this step) and
allowed to bind for 45–60 minutes at 4C. Plates were washed
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and bound phage were detected using 3,30,5,50-tetramethylben-
zidine substrate (Sigma-Aldrich, St. Louis, MO). The reactions
were quenched using equal volumes of 0.5 M sulfuric acid, and
the absorbance at 450 nm was measured.
Protein expression and purification
Fab proteins were purified from E. coli 55244 cultures harbor-
ing phagemids modified by the insertion of an amber stop
codon between the Fab and pIII proteins to facilitate secretion
of free Fab protein. 35 Clonal cultures were grown overnight at
30C in 2YT media supplemented with 50 mg/ml carbenicillin
and 25 mg/ml kanamycin. Cultures were centrifuged at 3000 g
for 10 minutes and pellets were re-suspended in 25 ml of a
phosphate limiting media, complete CRAP media,35 that sup-
ports induction of the phoA promoter. Ten ml re-suspended
culture was used to inoculate 1 L CRAP media, which was incu-
bated for 24 hours at 30C, pelleted, re-suspended in 25 ml
PBS, and frozen. Pellets were thawed, resuspended in 30 ml
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) contain-
ing 15 mg lysozyme (Bioshop) and 30 ml DNase I (deoxyribo-
nuclease I, Fermentus)) and lysed by sonication. Following
centrifugation to pellet cell debris, supernatants were loaded
onto fast-flow rProtein A-Sepharose (GE Healthcare) pre-
equilibrated in PBS. Columns were washed with PBS, eluted
with 50 mM NaH2PO4, 100 mM H3PO4, 140 mM NaCl, pH
2.5. Eluates were neutralized with 1 M Na2HPO4, 140 mM
NaCl and buffer exchanged into desired buffers using Amicon
10K MWCO centrifugal filters. Purified Fab proteins were ana-
lyzed by SDS-PAGE and quantified using a Bradford assay
(Bio-Rad) or the absorbance at A280 using an IgG conversion
factor.
NMR and R-region interaction experiments
NMR measurements were collected on a Varian Inova 800-MHz
spectrometer at 10Cwith a triple-resonance probe. Recorded data
were processed using NMRPipe 36 and analyzed using Sparky
(http://www.cgl.ucsf.edu/home/sparky/). Complete phosphoryla-
tion was achieved by incubation with PKA (NEB: P6000S), and
was monitored by mass spectrometry and NMR spectroscopy.7
HNCO spectra were recorded with 8 transients at 10C with
150 mM 15N13C R-region samples in the absence or presence of
200 mM Fab (1.33x molar excess) in 50 mM NaH2PO4 pH
7.20; 100 mM NaCl; 2 mM DTT; 10% (v/v) D2O.
Surface plasmon resonance
The kinetic parameters for interactions between Fabs and CFTR
domains were measured by SPR using a ProteOn XPR36 instru-
ment (Bio-Rad). Antigens were immobilized on a GLC chip by
amine coupling chemistry and serial dilutions of Fab in PBS with
0.05% Tween 20 were injected over the antigen and blank channels
(for reference subtraction) for 60 seconds at a flow rate of 100 ml/
min, followed by 10 minutes of buffer to monitor Fab dissociation.
The chip surface was regenerated with 0.85% H3PO4 prior to new
analyte injection. Kinetic parameters were determined by globally
fitting a reference cell-subtracted concentration series to a 1:1
(Langmuir) bindingmodel.
Epitope mapping of anti-CFTR fabs
An overlapping peptide array spanning the predicted cytosolic
regions of the human CFTR was used to identify the anti-CFTR
Fab epitopes. The array consisted of 15-residue peptides with 5
residues offset and a covalently attached biotin tag at the N-ter-
minus, synthesized by Mimotopes, The Peptide Company.
Unless otherwise stated, all binding steps were performed in PBS
containing 0.05% Tween 20, pH 7.4 (PBS/T) at room tempera-
ture and 3 washes with PBS/T between binding steps. For the
ELISA, approximately 10 picomoles peptide was captured onto
96-well Streptavidin plates (Nunc) for one hour. Plates were
blocked with 0.5% BSA in PBS/T for 0.5 hour and Fabs were
bound in PBS/T supplemented with 1% BSA for one hour, fol-
lowed by binding of horseradish peroxidase (HRP)-conjugated
anti-flag M2 antibody (Sigma) in PBS/T, 1% BSA for one hour.
The fluorescence generated by HRP in the presence of 60 mM
Amplex-Red was measured, using a fluorescence plate reader at
560 nm excitation and 590 nm emission wavelength. Back-
ground fluorescence was determined in the absence of peptide.
Full- length CFTR ELISA
His-Grab Nickel coated plates (Pierce) were coated with 75 ng/
well of Deca-His-tagged CFTR in PBS, 0.1% DDM overnight at
4C. Wells were blocked for 1 hour with PBS, 1% BSA, 5% nor-
mal goat serum (blocking buffer). Fifty ml Fab stocks (10 mg/
ml) in blocking buffer were added to wells in quadruplicates
and incubated for 2 hours. Wells were washed with PBS and
mouse anti-human kappa secondary antibody was added and
incubated for 1 hour. After washing, goat anti-mouse fluores-
cent antibody was added for 1 hour. Plates were washed with
PBS and scanned using Fuji FLA-5100 scanner. TIFF images
were quantified using ImageJ.
Western Blotting
Western blots were performed as described. 18 Briefly, 75 mg crude
membranes prepared from BHK cells expressing CFTR were run
on a 7% gel and transferred to nitrocellulose. Nitrocellulose was
blocked using 5% Carnation powdered milk in PBS. Fab protein
(10mg/ml) in blocking buffer was added and incubated for 2 hours.
Blots were washed with PBS between each antibody application.
Mouse anti-human kappa was added for 1 hour followed by fluo-
rescently tagged goat anti-mouse antibody. Blots were scanned
using a Li-Cor Odyssey fluorescent scanner.
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